Clinical Trials Logo

Clinical Trial Summary

The aim of this study was to evaluate efficacy and safety of Alpha Lipoic Acid(ALA) as an adjuvant in the management of patients with acute phosphide poisoning.


Clinical Trial Description

The study was carried out following approval of the research ethical committee of Tanta Faculty of Medicine on patients admitted to The Poison Control Unit (Emergency Hospitals, Tanta and Mansoura Universities) with acute phosphide poisoning in the period from January 2016 to January 2018. A written informed consent was taken from each patient or his/her guardians (if the patient was unable to participate in the consent process). Confidentiality of the data was maintained by making code numbers for each patient. The investigators planned to conduct a randomized clinical trial to evaluate efficacy and safety of LC as an adjuvant in treatment of patients with acute phosphide poisoning. Fifty patients was randomized to LC or a non LC in a 1:1 ratio (25 patients in each group). LC was given IV, as a dose of 1 g/8 hours. Patients was monitored and a detailed documentation of any adverse effect due to LC therapy was recorded.

This intervention represented an added treatment to the existing standard of care. All patients will continue to receive standard treatment, which was determined by the attending physician who maintained clinical responsibility for all patients. It consisted of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment. All the patients was followed up until discharge or death. All patients was subjected to:

I. History. II. Clinical examination. III. Laboratory investigations: At admission and repeated before discharge. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03953248
Study type Interventional
Source Kafrelsheikh University
Contact
Status Completed
Phase Early Phase 1
Start date January 2016
Completion date January 2018

See also
  Status Clinical Trial Phase
Completed NCT02273713 - The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) Phase 1/Phase 2
Terminated NCT00531076 - Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer Phase 1
Active, not recruiting NCT02397434 - Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer N/A
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Active, not recruiting NCT02649491 - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy N/A
Active, not recruiting NCT03975452 - Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer N/A
Terminated NCT00618917 - MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Not yet recruiting NCT02760823 - Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning Phase 2
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT00890448 - Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate N/A
Terminated NCT01760356 - Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
Recruiting NCT06044623 - Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients Phase 3
Completed NCT01091766 - Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine Phase 4
Completed NCT05277480 - Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Phase 2
Recruiting NCT03978949 - Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP) Phase 3
Completed NCT03491371 - Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use N/A
Completed NCT02143219 - Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Phase 2
Completed NCT02054741 - Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer N/A
Not yet recruiting NCT06087718 - Feasibility of the Maastro Applicator in Rectal Cancer N/A
Terminated NCT02512809 - Isoflurane-induced Neuroinflammation in Children With Hydrocephalus Phase 3